GSK2982772 is a highly selective, receptor-interacting protein-1 kinase (RIPK1) inhibitor being developed for the treatment of plaque psoriasis and other immune-mediated inflammatory diseases. This evidence concerns the gene RIPK1 and psoriasis vulgaris.